Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation

This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of OATP1B‐mediated drug–drug interactions (DDIs) relative to clinical probe rosuvastatin using nonlinear mixed‐effect modeling. Plasma and urine CPI data in the presence/absence of rifampicin were modeled to describe CPI synthesis, elimination clearances, and obtain rifampicin in vivo OATP Ki. The biomarker showed stable interoccasion baseline concentrations and low interindividual variability (<25%) in subjects with wildtype SLCO1B1. Biliary excretion was the dominant CPI elimination route (maximal >85%). Estimated rifampicin in vivo unbound OATP Ki (0.13 μM) using CPI data was 2‐fold lower relative to rosuvastatin. Model‐based simulations and power calculations confirmed sensitivity of CPI to identify moderate and weak OATP1B inhibitors in an adequately powered clinical study. Current analysis provides the most detailed evaluation of CPI as an endogenous OATP1B biomarker to support optimal DDI study design; further pharmacogenomic and DDI data with a panel of inhibitors are required.

[1]  H. Yamazaki,et al.  Pre‐incubation with cyclosporine A potentiates its inhibitory effects on pitavastatin uptake mediated by recombinantly expressed cynomolgus monkey hepatic organic anion transporting polypeptide , 2016, Biopharmaceutics & drug disposition.

[2]  S. Mandlekar,et al.  Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay , 2017, Drug Metabolism and Disposition.

[3]  Zhiwei Ye,et al.  Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1 , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  M. Niemi,et al.  Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.

[5]  K. Maeda,et al.  Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies , 2012, Clinical pharmacology and therapeutics.

[6]  Y. Lai,et al.  Quantitative assessment of the contribution of sodium‐dependent taurocholate co‐transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin , 2013, Biopharmaceutics & drug disposition.

[7]  H. Vainio,et al.  UDP glucuronosyltransferase and mixed function oxidase activity in microsomes prepared by differential centrifugation and calcium aggregation. , 2009, Acta pharmacologica et toxicologica.

[8]  M Jamei,et al.  ITC Recommendations for Transporter Kinetic Parameter Estimation and Translational Modeling of Transport‐Mediated PK and DDIs in Humans , 2013, Clinical pharmacology and therapeutics.

[9]  W. Humphreys,et al.  Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[10]  DL Kroetz,et al.  Metabolomic and Genome‐wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1 , 2016, Clinical pharmacology and therapeutics.

[11]  T. Tzeng,et al.  Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. , 2008, Current medical research and opinion.

[12]  Malcolm Rowland,et al.  Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential , 2012, Pharmaceutical Research.

[13]  W. Humphreys,et al.  Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects , 2017, Drug Metabolism and Disposition.

[14]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods , 2014, CPT: pharmacometrics & systems pharmacology.

[15]  M. Moore.  The biochemistry of heme synthesis in porphyria and in the porphyrinurias. , 1998, Clinics in dermatology.

[16]  X. Chu,et al.  Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. , 2017, Journal of pharmaceutical sciences.

[17]  Leon Aarons,et al.  Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach , 2014, Pharmaceutical Research.

[18]  X. Chu,et al.  Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans , 2015, Drug Metabolism and Disposition.

[19]  Mats O. Karlsson,et al.  Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption , 2008, Antimicrobial Agents and Chemotherapy.

[20]  K. Maeda,et al.  Quantitative Analyses of Hepatic OATP‐Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method , 2016, Clinical pharmacology and therapeutics.

[21]  K. Maeda,et al.  Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions , 2015, Drug Metabolism and Disposition.

[22]  D. Surry,et al.  Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  Y. Sugiyama,et al.  Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver , 2013, Clinical pharmacology and therapeutics.

[24]  Leon Aarons,et al.  Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data , 2015, British journal of clinical pharmacology.

[25]  W. Yue,et al.  Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport. , 2017, Journal of pharmaceutical sciences.

[26]  C. Battista,et al.  Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters , 2017, Clinical pharmacology and therapeutics.

[27]  K. Maeda,et al.  Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers , 2017, Pharmaceutical Research.

[28]  D. Bednarczyk,et al.  Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III , 2016, Xenobiotica; the fate of foreign compounds in biological systems.

[29]  Caroline A. Lee,et al.  Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design , 2015, Drug Metabolism and Disposition.

[30]  D R Mould,et al.  Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.

[31]  Prajakti A Kothare,et al.  Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. , 2014, British journal of clinical pharmacology.

[32]  Nikolaos Tsamandouras,et al.  Reduced Physiologically-Based Pharmacokinetic Model of Repaglinide: Impact of OATP1B1 and CYP2C8 Genotype and Source of In Vitro Data on the Prediction of Drug-Drug Interaction Risk , 2014, Pharmaceutical Research.

[33]  H. Kusuhara,et al.  Endogenous Probes for Drug Transporters: Balancing Vision With Reality , 2018, Clinical pharmacology and therapeutics.

[34]  W. Yue,et al.  Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport. , 2017, Journal of pharmaceutical sciences.

[35]  W. Humphreys,et al.  Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[36]  Maria Pia Saccomani,et al.  DAISY: A new software tool to test global identifiability of biological and physiological systems , 2007, Comput. Methods Programs Biomed..

[37]  Shiew-Mei Huang,et al.  Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction. , 2017, Journal of pharmaceutical sciences.

[38]  A. D. Rodrigues,et al.  Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides , 2017, Drug Metabolism and Disposition.